ALTIRIS THERAPEUTICS
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and Emtriva, which is used for the treatment of HIV Infection. Altiris Therapeutics was founded in 2005 and is based in Atlanta, Georgia.
ALTIRIS THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2005-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Total Employee:
501+
Status:
Active
Contact:
(404) 537-4961
Total Funding:
46.34 M USD
Similar Organizations
Bone-Rad Therapeutics
Bone-Rad Therapeutics is a Delaware corporation whose objective is to develop and market brachytherapy bone cement to treat tumors in bone.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Targeted Cancer Therapeutics
Targeted Cancer Therapeutics develops therapies for treating cancer.
TransCardiac Therapeutics
TransCardiac Therapeutics develops technologies to facilitate access to the human heart.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
ATDC
ATDC investment in Venture Round - Altiris Therapeutics
ATDC
ATDC investment in Series C - Altiris Therapeutics
ATDC
ATDC investment in Series B - Altiris Therapeutics
Georgia Venture Partners
Georgia Venture Partners investment in Series B - Altiris Therapeutics
Centrosome Ventures
Centrosome Ventures investment in Series B - Altiris Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Altiris Therapeutics
Talu Ventures
Talu Ventures investment in Series B - Altiris Therapeutics
H.I.G. Capital
H.I.G. Capital investment in Series B - Altiris Therapeutics
SR One
SR One investment in Series B - Altiris Therapeutics
MedImmune Ventures
MedImmune Ventures investment in Series B - Altiris Therapeutics
More informations about "Altiris Therapeutics"
Altiris Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Seed Round - Altiris …See details»
Altiris Therapeutics - 2025 Company Profile - Tracxn
Altiris Therapeutics - CXCR4 receptor antagonist for solid tumors. This company is not active anymore. Raised a total funding of $37.5M over 2 rounds from 8 investors. Founded by Dennis …See details»
Altiris Therapeutics - Contacts, Employees, Board …
Altiris Therapeutics has 3 current employee profiles, including Co-Founder James Snyder. Altiris Therapeutics has 3 board members and advisors, including …See details»
Altiris Therapeutics - Products, Competitors, Financials, Employees ...
Altiris Therapeutics's latest funding round is Series C. How much did Altiris Therapeutics raise? Altiris Therapeutics raised a total of $40.97M. Who are the investors of Altiris Therapeutics? …See details»
Altiris Therapeutics Inc Company Profile, Financial and ... - digitGaps
Altiris Therapeutics, Inc., develops and commercializes drugs to treat metastatic cancer. The company focuses on developing CXCR4 receptor, which acts as a mediator of cellular and …See details»
Altiris Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...
Jun 21, 2023 Explore Altiris Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 1 literature, Technology Platform:Small molecule drug, …See details»
Altiris Therapeutics funding & investors - Tracxn
Feb 28, 2025 Altiris Therapeutics has raised a total funding of $37.5M over 2 rounds from 8 investors. Investors include Frazier Healthcare Partners, SR One and 6 others. Their latest …See details»
ALTIRIS THERAPEUTICS, INC. Employer Identification Number EIN
Information about ALTIRIS THERAPEUTICS, INC.'s IRS EIN. Employer Identification Number 61-1506367 ALTIRIS THERAPEUTICS, INC. is a USA domiciled entity or foreign entity operating …See details»
Altiris - VentureRadar
LBV takes a unique model focused on lean operations, smart capital allocation, and diversified yet complementary nexus of 7 companies developing 10 first-in-class therapeutics. U.S. Precision …See details»
Altiris Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Altiris Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Altiris Therapeutics - Founders and Board of Directors - Tracxn
Feb 28, 2025 Altiris Therapeutics's founders include Dennis Liotta, Hyunsuk Shim and 1 other.See details»
Altiris Therapeutics Inc - Company Profile and News
Company profile page for Altiris Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Drug Discovery Companies | Emory University | Atlanta GA
Company Profile: Altiris Therapeutics, Inc. developed and commercialized orally administered small-molecule drug therapies. The company was developing drugs that inhibit CXCR4, a …See details»
Altiris Therapeutics - Crunchbase
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»
Altiris Therapeutics, Inc.:Company Profile & Technical Research ...
Altiris Therapeutics, Inc. is a company that provides Drug, Pharmacy and Therapeutics, CXCR4 and more. Altiris Therapeutics, Inc. is headquartered in United States Georgia. Altiris …See details»
MSX-122 - Drug Targets, Indications, Patents - Synapse - Patsnap
Mar 8, 2025 MSX-122: a CXCR4 antagonists Drug, Initially developed by Altiris Therapeutics, Inc., Now, its global highest R&D status is Phase 2, Mechanism: CXCR4 antagonists(C-X-C …See details»
Patents Assigned to Altiris Therapeutics, Inc.
Nov 15, 2012 Inventor: Altiris Therapeutics, Inc Chemokine receptor modulators. Patent number: 8338448 Abstract: The invention provides compounds of Formula (I) and pharmaceutically …See details»
Research programme: CXCR4 antagonists - Altiris Therapeutics
Nov 6, 2014 Metastatix (now Altiris Therapeutics) was discovering and developing a portfolio of chemical compounds that inhibit the CXCR4 chemokine receptor. Using a Research …See details»
MSX-122: Targets, Indications, Patents, and More - Synapse
May 7, 2023 MSX-122 is a CXCR4 antagonists Drug. Altiris Therapeutics, Inc. initially developed it.Its active indications include Hot Flashes, Vasomotor symptom, Vascular Diseases. …See details»
New study results reinforce Tagrisso as the backbone therapy for …
1 day ago New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy …See details»